James C. Lin
Lawyers
Filters
InSilico Medicine $60 million Series D financing
We are advising InSilico Medicine in connection with its $60 million Series D financing
PT Freeport Indonesia $3 billion notes offering
We advised the issuer on its Rule 144A / Regulation S notes offering
Provident Acquisition $1.02 billion combination with Perfect
We are advising Provident Acquisition, a SPAC, on the transaction
Carsome Group $290 million Series E funding round
We are advising Carsome on its Series E funding round
BeiGene RMB22.2 billion Shanghai IPO
The offering, equivalent to $3.5 billion, is the largest biotech IPO to date in 2021
CANbridge Pharmaceuticals HK$685 million IPO
We advised CANbridge Pharmaceuticals on its IPO and HKEX listing
FiscalNote business combination with Duddell Street Acquisition Corp.
We are advising Duddell Street, a SPAC, on the transaction
Sea $6.9 billion concurrent convertible notes and equity offerings
We advised the joint book-running managers on the concurrent offerings of convertible senior notes and ADSs
Baidu $1 billion sustainability notes offering
The investment-grade offering included notes due 2027 and 2031
Baidu $1 billion notes offering
We advised the underwriters on the investment-grade debt offering